Drug Trial Radar · NCT05094050
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 18, 2022
Primary completion
Mar 17, 2023
Study completion Mar 17, 2023
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease (PD) is a neurological condition, which means it affects the brain. This study will evaluate how ABBV-951 is absorbed under the skin of participants with PD when administered to arm, thigh and flank compared to the abdomen. ABBV-951 is an investigational drug being developed for the treatment of PD. Study doctors randomly assign participants to 1 of 4 groups, called treatment arms. Each treatment arm receives ABBV-951 administered in a different order in the arm, high, flank and abdomen. Approximately 12 adult participants over 30 years with a diagnosis of PD will be enrolled in approximately 10 sites in the United States. Participants will receive continuous (24hours/day) subcutaneous infusion of ABBV-951 for 2 consecutive days for each infusion site (arm, thigh, flank and abdomen), for a total duration of treatment up to 12 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will be confined at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Adverse events will be monitored throughout the study.
Conditions
- Parkinson's Disease
Interventions
ABBV-951Drug
Continuous Subcutaneous Infusion (CSCI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD)Time frame: Up to 8 Days
- Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of LDTime frame: Up to 8 Days
- Minimum Observed Plasma Concentration (Cmin) of LDTime frame: Up to 8 Days
- Degree of Fluctuation (DFL) of LDTime frame: Up to 8 Days
- Swing of LDTime frame: Up to 8 Days
- Maximum Observed Plasma Concentration (Cmax) of Carbidopa (CD)Time frame: Up to 8 Days
- Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of CDTime frame: Up to 8 Days
- Minimum Observed Plasma Concentration (Cmin) of CDTime frame: Up to 8 Days
- Degree of Fluctuation (DFL) of CDTime frame: Up to 8 Days
- Swing of CDTime frame: Up to 8 Days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Hospital /ID# 229974
Aurora, Colorado
Georgetown University Hospital /ID# 230224
Washington D.C., District of Columbia
Rush University Medical Center /ID# 229983
Chicago, Illinois
Carolina Phase 1, LLC /ID# 239836
Raleigh, North Carolina
The Movement Disorder Clinic of Oklahoma /ID# 238610
Tulsa, Oklahoma
Vanderbilt University Medical Center /ID# 230255
Nashville, Tennessee
Parkinson Disease Movement Disorders Clinic /ID# 245791
Austin, Texas
Texas Movement Disorder Specialists /ID# 238607
Georgetown, Texas
Baylor College of Medicine - Baylor Medical Center /ID# 239631
Houston, Texas
University of Utah Health Care /ID# 241219
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.